Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2000-8-25
pubmed:abstractText
Bcr-Abl contributes prominently to the development of most chronic myeloid leukemias (CMLs). Prior work has identified the adapter protein CRKL as a major substrate of the Bcr-Abl tyrosine kinase. CRKL can also bind via its first SH3 domain [SH3(1)] to specific sequences in Bcr-Abl. Cell-penetrating peptides were developed that bind with high affinity and selectivity to the SH3(1) domain of CRKL. They disrupt Bcr-Abl-CRKL complexes and strongly reduce the proliferation of primary CML blast cells and cell lines established from Bcr-Abl-positive patients. Activation-specific antibodies against phosphorylated MAP kinase (MAPK) showed that MAPK activity is down-regulated in blast cells treated with the CRKLSH3(1) blocker peptides. We conclude that the Bcr-Abl-CRKL complexes are largely dependent on the CRKLSH3(1) domain, that the central mitogenic cascade is down-regulated as a consequence of the disruption of CRKLSH3(1) interactions, and that CRKL therefore contributes to the proliferation of CML blast cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0892-6638
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1529-38
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:10928987-Adaptor Proteins, Signal Transducing, pubmed-meshheading:10928987-Amino Acid Sequence, pubmed-meshheading:10928987-Animals, pubmed-meshheading:10928987-Binding Sites, pubmed-meshheading:10928987-Calcium-Binding Proteins, pubmed-meshheading:10928987-Calreticulin, pubmed-meshheading:10928987-Cell Division, pubmed-meshheading:10928987-Cell Membrane, pubmed-meshheading:10928987-Cell Membrane Permeability, pubmed-meshheading:10928987-Fluorescent Antibody Technique, pubmed-meshheading:10928987-Fusion Proteins, bcr-abl, pubmed-meshheading:10928987-Half-Life, pubmed-meshheading:10928987-Humans, pubmed-meshheading:10928987-Leukemia, Myelogenous, Chronic, BCR-ABL Positive, pubmed-meshheading:10928987-Lymphocyte Activation, pubmed-meshheading:10928987-Mitogen-Activated Protein Kinases, pubmed-meshheading:10928987-Molecular Sequence Data, pubmed-meshheading:10928987-Nuclear Proteins, pubmed-meshheading:10928987-Peptides, pubmed-meshheading:10928987-Protein Binding, pubmed-meshheading:10928987-Rats, pubmed-meshheading:10928987-Recombinant Fusion Proteins, pubmed-meshheading:10928987-Ribonucleoproteins, pubmed-meshheading:10928987-Spectrometry, Fluorescence, pubmed-meshheading:10928987-Tumor Cells, Cultured, pubmed-meshheading:10928987-src Homology Domains
pubmed:year
2000
pubmed:articleTitle
Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.
pubmed:affiliation
Laboratory of Molecular Oncology, MSZ, Universität Würzburg, Germany.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't